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A reversed-phase High Performance Liquid Chromatography (HPLC) protocol for amino 
acid analysis using o-phthaladehyde (OPA) as the pre-column derivatization agent was 
set up. The HPLC system was equipped with an autosampler as well as an auto-injector 
worked under a commercial software. Two mobile phases were used for gradient elution. 
The method used methanol as the solvent to precipitate the protein and a Cig column ( 250 
X 4.6 mm I.D., 5|im particle size) for separation. In 75 minutes, 27 amino acids in plasma 
were resolved. Automatic derivatization was possible after optimization of the sample 
volume, derivatization reagent volume and concentration, and the derivatization reaction 
time. Analytical performance was satisfactory. Averaged within-run and between-run 
precision were 4.7% and 7.3% respectively. Plasma samples for amino acid analysis 
should be stored at -20�C without affecting the results. 
The free amino acid profiles of 10 colorectal cancer patients, 12 lung cancer patients and 
12 nasopharyngeal cancer patients were studied and compared with 17 healthy control 
subjects. All the cancer patients were newly-diagnosed cases with no other underlined 
diseases. Aspartic acid. Glutamic acid and 3-methyUiistidine were found to be elevated in 
all three kinds of malignancy diseases. Although some alteration in concentration was 
found in some amino acids, no specific change was seen for their total amino acid ’ 
branched-chain�aromatic, essential, and non-essential amino acid contents as compared 
With the control group. Lung cancer group showed elevation in essential amino acid and 
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ABSTRACT 
A reversed-phase High Performance Liquid Chromatography O^PLC) protocol for amino 
acid analysis using o-phthaladehyde (OPA) as the pre-column derivatization agent was 
set up. The HPLC system was equipped with an autosampler as well as ati auto-injector 
worked under a commercial software. Two mobile phases were used for gradient elution. 
The method used methanol as the solvent to precipitate the protein and a Cig column ( 250 
X 4.6 mm I.D., 5pm particle size) for separation. In 75 minutes, 27 amino acids in plasma 
were resolved. Automatic derivatization was possible after optimization of the sample 
‘ 
volume, derivatization reagent volume and concentration, and the derivatization reaction 
time. Analytical performance was satisfactory. Averaged within-run and between-run 
precision were 4.7% and 7.3% respectively. Plasma samples for amino acid analysis 
should be stored at -20°C without affecting the results. 
The free amino acid profiles of 10 colorectal cancer patients, 12 lung cancer patients and 
12 nasopharyngeal cancer patients were studied and compared with 17 healthy control 
subjects. All the cancer patients were newly-diagnosed cases with no other underlined 
diseases. Aspartic acid, Glutamic acid and 3-methyUiistidine were found to be elevated in 
all three kinds of malignancy diseases. Although some alteration in concentration was 
found in some amino acids，no specific change was seen for their total amino acid， 
branched-chain, aromatic, essential, and non-essential amino acid contents as compared 
with the control group. Lung cancer group showed elevation in essential amino acid and 
^ g h t be due to dietary factor. 
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1. INTRODUCTION 
1.1 AMINO ACID ANALYSIS BY HIGH PERFORMANCE 
LIQUID CHROMATOGRAPHY 
1.1.1 History and Development 
In 1950s, Moore and Stein (Moore & Stein, 1951) developed the classic ion-
exchange column chromatography for amino acids. The amino acids were 
separated according to their positive or negative charges at different pH, created 
by a series of elution buffers with different pH. The eluted amino acids react 
with ninhydrin so as to be detected as colored products. Spackman et al (1958) 
automated the procedures. The colour intensity developed by ninhydrin and the 
amino acids were automatically recorded. This set-up formed the basis of amino 
acid analyzer. In 1959，Beckman introduced the first commercial amino acid 
analyzer. A series ofbuffers pumped by the buffer pump passed through sample 
loader and carried the sample into the resin. Ninhydrin was pumped to the mixing 
manifold, and there it mixed with the amino acid effluent from the resin. After 
mixing in the reaction coil, the mixture reached the detector . Signals were 
generated in the detecor and recorded automatically. After the introduction of 
High Performance Liquid Chromatography (HPLC) in 1960s, the ion-exchange 
separation can be incorporated into the HPLC procedures. This led to improved 
both efficiency and sensitivity. For the next twenty years onward, the ion-
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exchange liquid chromatography became the most popular method for amino acid 
analysis in clinical laboratories. 
The advent reversed-phase HPLC provide an attractive alternative for amino acid 
analysis. The reversed-phase HPLC allow the pre-column reaction with 
derivatization agent. In pre-column derivatization, derivatization agent did not 
need to be pumped continously to mix with the amino acid effluent. Less reagent 
was consumed a clearer chromatographic background was produced. No 
undesirable amino acids in the elution buffer reacted with the derivatization 
agent. Sensitivity was greatly improved. 
1.1.2 Separation mechanism 
In ion-exchange chromatography, the ion-exchangers are sulphonated fiuictional 
group on the resin. The resin consists of small beads of polystyrene. The 
polystyrene is sulphonated by sulphuric acid to attain a negative charge. It then 
reacts with divinylbenzene to enhance the cross-linkage property. The negatively 
charged groups are associated with mobile counter ions�usually ithium. They 
have no true pores in them. The bead matrix can serve as apparent pores and 
retards the movement of the ions through the column. In order to increase the 
efficiency of separation, smaller bead size and high pressure are favored (Walker 
& Mms, 1995). 
Amino acids are zwitterions carrying both positive amino groups and negative 
carboxyl groups. The net charge depends on the pH of the enviroment. At low 
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pH, the positive amino groups interact with the sulfonated ion-exchange resin so 
that the basic amino acids are retained, but not the acidic amino acid with the 
suppressed carboxyl groups. The positive amino groups exchanged the position 
of the positively charged lithium, which was originally associated with the 
suphonated ions. The acidic amino acid at such low pH has a relatively weaker 
interaction with the sulfonated ion-exchange resin, they are eluted first. As the 
pH increases, some other amino acids lose all the charges at their isoelectric 
point and elute out. Separation is due to primarily to differences in the isoelectric 
points and follows the general order: acidic, neutral and finally basic. 
In reversed-phase liquid chromatography, the stationary phase in the analytical 
column, is hydrophobic, while the mobile phase is polar. Non-polar compounds 
can be easily retained by the column while the relative polar compounds are 
easily eluted out by the polar mobile phase. 
The amino acids can carry positive amino groups and negative carboxyl groups. 
At pH lower than its isoelectric p o i n t� t h e y exist predominantly as positive 
charge while at high pH, negative charge. Pre-column derivatization in reversed-
phase HPLC aims at destroying the zwitterion nature of the amino acid by 
reacting with one of the charged group so that a suitable pH can be employed to 
render the amino acids hydrophobic. Besides, after separation, the derivatized 
amino acids, could be detected by sensitive method ofdetection. 
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1.1.3 Derivatization 
Derivatization of the amino acids enliences detectability. It is important since 
only a few amino acids can be detected by general signal detector, such as 
colorimetry or fluorimetry. Phenylalanine, tyrosine and tryptophan can absorb 
UV light around wavelength 250-280 nm. Although at wavelength below 210 
nm, most amino acids show strong UV absorption, the absorption ofthe solvents 
and impurities become so significant that it causes serious baseline problem. 
Without derivatization, only tyrosine and tryptophan exhibit significant emission 
when excited at 254 nm (Perrett, 1985). 
Derivatization can be carried out after or before the amino acids being separated 
in the analytical column. Post-Column derivatization aims at rendering the amino 
acids after eluted out from the column readily detectable by some signal detector. 
Smce the derivatization is added only after elution, the amino acids must use 
some oftheir own physical properties such as charges so as to be separated in 
the analytical column. After separation, a metering pump is necessary to 
continuously pump the derivatization agent into the column eluent. The principal 
advantage of post-column derivatization is that the underivatized amino acids are 
applied into the column. Derivatives stability in the separation column or 
derivatization reaction completeness is not being major problem in post-column 
derivatization. However, trace amounts of undesirable amino acids in the buffers 
when eluted'out from the column，can react with the derivatization agents and 
causes the fluctuation in the baseline ofthe chromatogram. 
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Pre-colunm derivatization should make the sample readily detectable as well as 
create or retain the property that is employed for separation process. Pre-colunm 
derivatization is economical on derivatization reagent use since no continuos 
pumping the reagent is necessary as in post-column reaction. The derivatized 
samples, however, may be unstable during separation or the derivatization for 
some amino acids are not complete The loss of the amino group in the amino 
acids after derivatization makes the traditional ion-exchange chromatography 
applicable. The carboxyl group becomes significant in determining the mode of 
separation. 
Different derivatization agents have been developed. A good derivatization 
agent should react with all the different amino acids. It should react with amino 
acids only and distinct product should be formed for each individual amino acid. 
It itselfshould be stable and it itself will not generate signal response. 
Derivatization agent that is most commonly used for post-column reaction is 
ninhydrin, while o-phthaladehyde (OPA) is a good alternative. Post-column 
derivatization is the conventional procedure for ion-exchange HPLC. While the 
pre-colunm reaction, which is usually preceding the reversed-phase HPLC 
separation, examples of derivatization agent include o-phthaladehyde (OPA), 
fluroeny-methyl chloroformate (FMOC) and dansyl chloride (Dns-Cl). 
Ninhydrin was first introduced by Moore and Stein in 1950s. It is the classic 
reagent to detect amino acids over 30 years.. The amino group ofprimary amino 
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acids reacts with two molecules of hydrindantin, the reduced form of ninhydrin, 
to form Rhuman purple with maximum absorption at 570 nm. A yellow adduct, 
with maximum absorption at 440 nm, is formed with secondary amino acids, 
proline and hydroxyproline. At an elevated temperature of 120°C, the reaction 
only takes 2 to 3 minutes to complete. Such reagent can provide adequate 
sensitivity while maintaining resolution. It can react with both primary amino 
acids as well as secondary amino acids, proline and hydroxyproline. Some drugs 
can react with Ninhydrin and cause interference. Some antibiotics such as 
ampicillin and kanamycin can generate abnormal peaks. 
o-phthalaldehyde (OPA) is another popular post-column derivatization agent, 
and nowadays becomes the most popular pre-column derivatization agent. OPA 
can render the amino acids more hydrophobic, by reacting with the amino group 
on them. It reacts with primary amino acids at an alkaline pH in the presence of 
a thiol, 2-mercaptoethanol, to form adducts detectable by fluorescence detector. 
The two hydrogen atoms linked to the nitrogen atom react with the two aldehyde 
groups on the OPA molecule and formed an isoindole derivatives, while the 
carboxyl end remain unchanged. The fluorescence signal produced is very strong, 
and it can give 10-1000 times higher sensitivity than ninhydrin (Ersser & Davy, 
1991). The reaction takes 2 to 3 mintes to complete in room temperature. The 
reagent itself does not give fluorescence and no interference peak will be 
produced. However, some problems are still associated with OPA derivatization. 
Firstly, the OPA derivatives are not very stable. Its half-life ranges from 2 to 72 
niinutes (Walker, 1995). Secondary, it does not react with secondary amino acids 
directly, since they do not have two free hydrogen atoms linked to nitrogen atom 
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for isoindole derivative formation. Thirdly, Transformation of cystine and 
homocystine to cysteine and homecysteine by iodoacetate is a necessary step to 
render them detectable. 
FMOC can react with secondary amino acids�proline and hydroxyproline in 
addition to primary amino acids. Besides, the derivatives formed are stable for 
several days. The stability of the derivatives makes manual derivatization 
possible (Haynes et a l�1 9 9 1 ) . The detection sensitivity can be down to 
fetomolar. The principal disadvantage of its function as derivatization agent is 
that it itself generates fluorescence and causes interference peaks. Therefore 
excessive reagent must be removed before the derivatives are applied to column 
for separation. The extraction solvent most often used is pentane (Miller et al, 
1990). Some amino acids, such as histidine and tyrosine form mono- and di-
substituted derivatives. 
5-dimethylaminonaphthalene-1 -sulphonyl chloride is commonly known as Dansyl 
chloride. It can react with both primary and secondary amino acids at dark in the 
room temperature. An extraction process and evaporation step are required prior 
to derivatization. Derivatization takes 3-5 hours or sample can be derivatized 
ovemight. The derivatives once formed are stable for at least 96 hours 
(Weidmeier, 1982). Detection is usually by fluorescence or UV absorbance. 
Problems as derivatization agent includes poor yield of derivatives, multiple 
peaks ofthe derivatives and light sensitivity ofthe derivatives. 
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Blankenship et al (1989) developed an automatic two-step derivatization 
technique to overcome great disadvantage of OPA that it does not react with 
secondary amino acids such as proline and hydroxyproline even though it can 
ensure high sensitivity and produce promised result,. In the first step, all primary 
amino acids react with the OPA reagent containing 2-mercaptoethanol. During 
the second step, the reaction mixture of OPA derivatives is treated with FMOC-
C1 to derivatize the unreacted secondary amino acids. Both reactions are rapid 
and the derivatives produced are strongly fluorescence. Bartok et al (1994) 
speeded-up the separation by using a relatively short column (10 cm X 4 mm H)) 
filled with Hypersil ODS packing. The total analysis time, including pre-column 
derivatization, separation, column washing and re-equilibration cycles, was only 
18 minutes. 
1.1.4 Deproteinuation 
Protein must be removed from the sample before applied to the analytical 
column. In ion-exchange chromatography, the protein can clog the resins and 
cause peak spreading and increase of back pressure in the column. In reversed-
phased HPLC, the protein can prevent or interfere with the derivatization 
process. 
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Sulphosalicyclic acid (SSA) precipitation is a common deproteinizing agent for 
ion exchange analysis. The acid does not need to be removed from the 
supernatant before analysis, and the pH is close to the application pH. 
Although sulphosalicyclic acid gives promised result for ion exchange analysis. It 
is not suitable for reversed-phase HPLC analysis. Liu & Worthen (1992) did not 
have success in using SSA as the deproteinization agent for the analysis of 
plasma amino acids by reversed-phased HPLC with automatic pre-column OPA 
derivatization. They attributed their failure to the strong acidic nature of SSA 
inhibits the formation of OPA-amino acid derivatives. Moreover, SSA has a peak 
that superimposes on some of the early elution amino acid peaks. Therefore, they 
recommended an ultrafiltration for protein removal. During ultrafiltration, the 
plasma is deprotemized by filtration of plasma through a ultrafiltration 
membrane. Protein is retained by the membrane while ultrafiltrates with free 
amino acid pass through and are collected in the filtrator cup. They demonstrated 
that the recoveries of the standard amino acids were excellent, ranging from 95% 
to 102%. 
The addition of several volumes of acetonitrile, acetone or alcohols to the 
sample, followed by brief centrifugation, is a rapid precipitation method. It gave 
an economic means of protein removal. All these worked well under neutral pH 
condition. (Davey& Ersser, 1990). 
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1.1.5 Ion-exchange or Reversed-phase HPLC 
From 1960s, manufacturers started to manufacture the dedicated amino acid 
analyzer, using the ion-exchange chromatography. Over 30 years, automatic 
sampler�improved resins and data handling had been added to the features of the 
analyzer. Nowadays the ion-exchange post-column HPLC is now the basic 
configuration of a commercial amino acid analyzer. It can produce 
chromatogram of well-resolved amino acid peaks. The drugs that cause 
interference have been identified. (Walker,1995) Parallel the developments of 
commercial amino acid analyzer, technical advancements favor the development 
of reversed-phase HPLC for amino acid analysis. The HPLC equipment has 
developed the sophisticated pulseless gradients pump, automatic sampler, 
varieties of column packing, controllable column temperature as well as optional 
pre-or post-column derivatization. By change of mobile phase, column and 
detector, operator can shift to other applicator with ease. The flexibility and 
versatility increase the popularity of using reversed-phase HPLC for amino acid 
analysis. More than ten samples can be processed in an overnight run. The 
sensitivity is higher as well (Tumell & Cooper�1982). 
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1.2 AMINO ACID PATTERN IN CANCER PATIENT 
1.2.1 Cancer cachexia 
Cancer cachexia is a complex condition developed in most cancer patients 
characterized primarily by decrease food intake and progressive tissue loss that is 
manifest clinically as anorexia and weight loss. (Pisters & Brennan, 1996) The 
term cachexia is derived from the Greek words kakos, meaning bad and hexis, 
meaning condition. The extent of cancer cachexia depends on the site of 
malignancy as well as the type of tumour. 
Nutritional deterioration and alteration of body biochemical metabolism, caused 
by cancer cachexia, limited the patient to respond to rigorous antineoplastic 
therapy. (Dewys, 1980) It has been estimated that the death of two-third ofthe 
cancer patients could be partly due to cancer cachexia. (Lawson, 1982) 
The study ofmechanism of cancer cachexia is worthwhile so as to minimize the 
bad effects to improve the prognosis of the cancer patients. 
h2.2 Causes of cancer cachexia 
Anorexia and altered biochemical metabolism are causes of cancer cachexia. 
Anorexia will results in imbalance of nutrients intake to meet body metabolic 
demands�and cause tissue depletion. Forced feeding cannot reverse or improve 
11 
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the condition and change in patient body metabolism must contribute 
significantly to cancer cachexia. Increase consumption ofthe tumour cannot fully 
explain the situation of weight loss as well as the change in body metabolism. 
Tumour removal can improve cancer cachexia, with improved anorexia and 
subsequent weight gain as well as restoration ofmetabolism disturbances. 
1.2.3 Cytokines 
It is postulated that some mediators may be involved in the process of alter 
biochemical metabolism. Illig etal (1992) took serum from tumour-bearing rats 
and injected into normal control rats. The control rats developed cachexia. They 
concluded some mediators in the blood were involved in cachexia wasting and 
cancer cachexia was transmissible. The circulating mediators are produced by the 
tumour or by the host in response to the tumour. Cytokines are host-derived 
protein molecules secreted by macrophages in response to pathological stimuli. 
(Kristine et al，1994) They transmit signal between cells in response to a variety 
ofpathological stimuli. 
Tumour necrosis factor (TNF) appears likely to play a role both in humans and in 
animal models. Administration of recombinant TNF to animals can induce weight 
loss and the metabolic alterations observed in cancer cachexia patients. It has 
been suggested that TNF produces an effect on lipid metabolism through an 
inhibition of the enzyme lipoprotein lipase (Beutler et al, 1985). Miibition of 
lipoprotein lipase results in hypertriglyceridemia. 
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Other cytokines that may play role in cancer cachexia includes interleukin-1 (IL-
1), interleukin-6 (H^-6) and interferon gamma (IFN-y). It seems the cancer 
cachexia is a complex syndrome that involves an array of cytokines interaction 
and no single cytokine alone can produce the cachexia effects. No single 
cytokine is dominant over the others. 
1.2.4 Metabolic Alteration in cancer cachexia 
Cancer-associated metabolic abnormalities include altered energy expenditure, 
protein metabolism, carbohydrate metabolism and lipid metabolism. Patients 
show signs of hypoalbuminaemia, hypoproteinaemia, glucose intolerance ,lactic 
acidosis and hypertriglyceridemia 
Hyltander et al (1991) studied 106 cancer patients and 96 non-cancer-bearing 
controls and demonstrated that the cancer patients had an elevating resting 
energy expenditure to the control patients. Elevated energy expenditure is 
probably due to the metabolism of the tumour. Therefore, cancer cachexia will 
decrease the body energy store and upset its balance state.. 
Jeevanadam et al (1984) demonstrated that the whole-body protein turnover was 
higher in the cancer patients than in the non-cancer patients and the starved 
normal subject respectively. Tumours metabolize the body protein. The 
peripheral muscle mass decreases due to increase protein catabolism. The 
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peripheral muscle protein was broken down into amino acids that form the 
substrate for protein synthesis in the liver. The body protein turnover rate 
increases (Carmichael, 1980). These alterations upset the body defense 
mechanism against stress as well. 
Tumours will use up body glucose with the production of lactate. Lactate 
recirculate back to liver where lactate is re-used to synthesize glucose. As a 
result, the liver lose glucose as well as energy to make up glucose. 
Animal studies suggest that tumour induced the production of some fat 
mobolizing mediators which can increase lipid mobilization and fatty acid 
oxidation, but decrease the fat biosynthesis (Harrison, 1996). 
1.2.5 Amino Acid Studies 
Cancer cachexia can cause alteration in protein metabolism and 
gluconeogenesis. Amino acids are the substrates for these processes. Amino acid 
studies can reveal the nutritional status of the patients and the mechanism in 
derangement metabolism. 
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Clarke et al (1978) divided the subjects into four groups: 1) normal volunteers, 
2) cancer patient without weight loss, 3) cancer patients with 20% weight loss 
and 4) non-cancer malnourished patient with 20 % weight loss. They 
demonstrated that mahiourished subjects without cancer have lower body 
branched-chained amino acids (BCAA) when compared with normal subjects. 
However the cancer patients have no significant decrease in the BCAA. Glycine 
levels were lower in weight losing cancer patients but higher in weight losing 
malnourished non-cancer-patients. Plasma levels of valine, leucine and 
methionine were significantly elevated in weight-losing cancer group as 
compared with the non-cancer malnourished patients. Plasma levels of alanine, 
isoleucine and valine were significantly elevated cancer patients without weight 
loss when compared with normal subjects. 
Although Clarke could show some amino acids pattern in cancer patients as well 
as those under nutrition, a heterogeneous combination of different types of 
cancer patients made the interpretation difficult. Therefore, no conclusions as to 
cancer specific alterations in plasma amino acid concentrations can be made. 
Burt et al (1983) carried out a homogenous group of oesophagus cancer patients 
studies. They found that the Branched-chain amino acids were noticeably 
increased in the weight-losing cancer patients. Such finding differentiates the 
malnutrition patients in Clarke studies which showed decrease in those amino 
acid levels. 
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Levin et al (1983) compared amino acid levels of weight-losing lung cancer 
patients with weight-losing tuberculosis patients. Multiple decreases in amino 
acids were noted as compared to weight-losing tuberculosis patients.The 
decrease in amino acids included several essential branched chain amino acids, 
as well as some non-essential amino acids. 
Beenegard et al (1984) studied the malnourished cancer patients and compared 
amino acid levels with non-cancer malnourished and well-nourished controls. 
They noted that both the essential and non-essential amino acid levels were lower 
in malnourished cancer patients when compared with the malnourished controls. 
Contrary to the previous findings, they found that the BCAA in both 
malnourished groups were the same. When the malnourished cancer patient was 
compared with the normal controls, the BCAA levels were decreased. 
Ching & Pang (1984) measured plasma amino acid levels in 13 patients with GI 
malignancies. There were no differences in plasma amino acids levels between 
the GI malignant patients and normal control group. Only threonine and glycine 
were lower in head and neck cancer group, while other amino acid preserved. 
Hepatic metastases had decreased levels of both essential and non-essential 
amino acids. 
h the study by Norton et al (1985), they classified the patient by tumour types 
and studied plasma amino acids in control group and compared the results to 
different group. Only the proline level was significantly lowered in osteosarcoma 
3nd sarcoma patients. Lymphoma patients had significantly lower histidine and 
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arginine levels versus controls. Esophagus carcinoma patients with 22% weight 
loss, had a significant reduction in most essential and non-essential amino acids. 
Naini et al (1988) studied the oesophagus and lung cancer patients and compared 
them to age-matched benign disease patient with no weight loss. As compared to 
the control group, either of the group had significant difference in essential amino 
acid levels except a decrease in tryptophan. Alanine and arginine levels were 
significantly lower in the lung cancer patients. 
Pisters et al (1992) studied amino acid levels in 6 GI cancer patients and 
compared them to 5 age-matched normal volunteers. There were no differences 
in branched chain, essential or non-essential amino acids in the 2 groups. 
Zhang & Pang (1992) classified 63 cancer patients according to the cancer type 
and studied their amino acid levels. They grouped the patients as lung cancer 
(31 patients), liver cancer (16 patients), colon cancer (10 patients) and breast 
cancer (6 patients). The amino acid levels of each group were compared with a 
control group which consists of 16 aged-match healthy adults. The results 
showed that aspartic acid and glutamic acid were significantly increased in all 
four groups of cancer patients. Amino acid patterns of breast cancer patients 
were most similar to the healthy group. Colon cancer patients showed increase 
levels in glycine, alanine and taurine. The liver cancer patients could conserve the 
branch-chained amino acids while most of the non-essential amino acid showed 
significant elevation. For lung cancer patients, there were no change in branch-
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chained amino acids leucine and isoleucine. However many of the essential and 
non-essential amino acids showed significant decrease. 
Body amino acid requirements are altered in the tumour-bearing state. Leucine 
requirement has shown to be increased in the presence of rapidly growing murine 
tumour (Lazo, 1980). Some malignant cells have specific requirements for 
methionine (Tisdale, 1980), serine and threonine (Pizer & Reagan�1972). 
Removal one of the amino acid by the tumour would lead to a depression of host 
protein synthesis, since normal protein synthesis requires the flill spectrum of 
amino acids. Disposal of the remaining amino acids has been postulated to 
explain the abnormal gluconeogenesis seen in cancer patient (Stein, 1978). 
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1.3 METHODOLOGY CHOSEN 
A reverse-phase HPLC pre-column derivatizatiom method was going to be 
established to analyse the plasma amino acids. Compared with ion-exchange 
HPLC using post-column derivatization , the former had several advantages over 
the latter. Firstly, the efficiency of separation was higher in reverse-phase HPLC. 
Post-column derivatization was a tedious procedure while pre-column 
derivatization took several minutes to complete and usually done by automatic 
sampler. Pre-column derivatization could give very high sensitivity. No 
undesirable amino acids in the mobile phases would react with the derivatization 
agent and eluent baseline could be very stable. Lastly the whole set of 
instrument was not a dedicated one and could be easily shifted to other analysis. 
o-phthaladehyde (OPA) was the derivatization of choice since it could give very 
high yield in fluorescence signal. The limit of detection could be down to 
fetomolar. It took about two minutes for he reaction to complete. The reaction 
required no elevation of temperature. 
Deproteinization could be easily carried out using methanol precipitation method. 
Since the OPA itself was not fluorescence, no subsequent extraction of excess 
reagent by organic solvent was necessary. 
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In the presence of 2-mercaptoethanol, which was a reducing agent, OPA reacts 
with the amino group of primary amino acids to a produce fluorescence product 
alkyl-substituted isoindole. The reagent has no reaction with the secondary amino 
acids. 
An autosampler was used to automate the derivatization steps. The autosampler 
took accurate amounts of sample and derivatization reagent from appropiate vial 
position in the instrument, mixed them and hold them for exactly a predefined 
interval for derivatization reaction to proceed, and finally inject them into the 
analytical column. Both the volume taken and duration for reaction were critical 
to produce reproducible result. 
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1.4 PATIENT SAMPLE CHOSEN 
Colorectal cancer, lung cancer and nasopharyngeal cancer are three very 
common disease in Hong Kong leading to mortality. In the study, the amino acid 
patterns of newly-diagnosed patients of the above cancer disease were studied.. 
In order to minimise other variables that may affect the amino acid 
concentrations, the patients should be free from other diseases such as liver 
disease, heart disease, renal disease and endocrine disease. Besides, the patients 
should not received any vigorous chemotherapy or radiotherapy. 
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2. OBJECTIVES 
1. To establish a fully automated reverse-phase pre-column derivatization HPLC 
procedure for plasma amino acid analysis. 
2. To study the amino acid pattems of colorectal, lung and nasopharyngeal 
cancer patients in Hong Kong. 
22 
3. MATERIALS AND METHOD 
3.1 APPARATUS 
3.1.1 HPLC System 
HPLC Hewlett Packard (Palo Alto, California, USA) HP 1050 with 
autosampler and pumps. The instrument has the capability that the needle probe 
can randomly access different vial positions under program assigned thus made 
derivatization of sample to be done automatically. 
3.1.2 Column 
A Carbon 18 (C18) column, 250 mm X 4.6 mm I.D. with 5 |im particle size, was 
used,. It was made up of silica with a C18 hydrocarbon chain chemically bonded 
to the surface to reduce the polarity，sometimes referred as octadecyl silica 
(ODS). A guard column was installed just before the main analytical column to 
offer some protection for the latter. 
3.1.3 Detector 
A fluorescence detector HP 1046A was used. The excitation wavelength was 230 
nm while the emission wavelength was 418 nm. 
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3.1.4 ChemStation 
A desktop computer installed with software to monitor the operation of the 1050 
pump and injector as well as the 1046A fluorescence detector. Besides, 
chromatographic signals can be integrated and analyzed and stored. 
3.2 REAGENTS 
3.2.1 Reagent and Chemical source 
All the chemicals and reagents, unless otherwise stated, were obtained from 
Sigma Chemical Company, St. Louis, USA. 
3.2.2 Mobile phase 
Amino acid separation was carried out by gradient elution. Two mobile phases 
were used. Different composition of the two mobile phase were mixed at 
different time during the run before being pumped to the analytical column. The 
composition of the mobile phases was adapted from Tumell & Cooper (1982). 
Solvent A consists of water, acetonitrile and a buffer. To prepare the buffer, a 
solution of 0.25M sodium propionate and 0.35M of Sodium dihydrogen 
phosphate was adjusted to pH 6.5 using 5 N NaOH. Then 150 ml of such buffer 
was mixed with 80 ml acetonitrile and 770 ml water. This makes up the total 
volume to 1000 ml with acetonitrile:buffer:water ratio equals to 8:15:77. 
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k. 
Solvent B consists mainly of organic solvent. It has a 
acetonitrile:methanol:dimethylsuphoxide:water ratio 30:25:3:42. In 1000 ml such 
solution, it consists of 300 ml acetontrile, 250 ml methanol, 30 ml 
dimethylsulphoxide and 420 ml water. 
The organic components of mobile phase were all filtered through 0.45 ^m 
nitrocellulose membrane while the inorganic parts were filtered through 0.45 |im 
flurocarbon membrane. The membrane were obtained from Millipore 
Corporation, (MA, USA). 
The two solvents were degassed by pumping helium gas into them for a few 
minutes. 
3.2.3 Derivatization Reagent 
0-phthaladehyde (OPA) stock solution was prepared by dissolving 50 mg 
powder in 1 ml methanol. The stock solution was put in brown bottle in 4°C for 
at most three weeks. A 0.4 M sodium borate / boric acid buffer was then 
prepared To prepare a working OPA solution, 1476 ^1 ofthe borate buffer was 
used to mix with 60 ^1 stock OPA solution and 24 i^l 2-mercaptoethanol. The 
final solution has a OPA concentration 1.92 mg /ml and 2 mercaptoethanol 
concentration 1.5%. The working OPA solution was stable for only one day. 
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3.2.4 Standard preparation 
For each amino acid standard solution, suitable amount of amino acid standard 
was weighed to make 1 ml of stock solution with concentration of 40 |imoL^ml 
in O.lM HCL, except the 3-methylhistidine due to amount available. From the 40 
^moL'ml or 40,000 ^moLl. stock solution, suitable volume of each amino acid 
was taken out to make up the two levels of composite standards. The high 
standard has a concentration five times than that of the low standard. Their 
concentration ranges from 40 to 1000 ^imol/L depends on their concentration 
usually found in human body. The composite standards were aliquoted and stored 
in a -30�C freezer. Table 3.1 illustrate the amount of individual amino acid used 
as well as the volume of the stock standards used to make up 10 ml of each level 
ofcomposite standard. 
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Table 3.1 Composite Standard Preparation 
Slflma Standard Prepare stock standard Composrte standard f10ml> 
Amount Volume Concentration HIGH STD. LOW STD. 
F.W. Available weighed 0.1MHCL stock req. FlnalConc. stockreq. FinalConc 
哪 mg ml umoM umolA. "/ umoUL "/ umolA. 
Aspartic acid ^ ^ ^ V6 ^ 40：^ ^ ^ j g ^ 5 — 
Glutamic acid w . i 100.000 5.88 1.0 40 40,000 100 4 0 0 20 8 0 
Cystine 240.3 26.000 9.61 1.0 40 40,000 1Q0 4Q0 20 8 0 
Asparagine iso.i 25,000 e.oo 1.0 40 40,000 50 2OO 10 4 0 
Serine ios.i 25.000 4.20 1.0 40 40,000 ioO 4 0 0 20 80 
Histidine 1w.2 25.000 6.21 1.0 40 40,000 50 2OO 10 4 0 
Glutamine i4s.i 25.000 5.84 1.0 40 40,000 250 1000 50 200 
Glycine 75.07 100.000 3.00 1.0 40 40,000 250 1000 50 2 0 0 
Threonine ii9.i 1.000 4.76 1.0 40 40.000 ioo 4 0 0 20 8 0 
Citruline 175.2 5.000 7.01 1.0 40 40,ooo 50 2OO 10 4 0 
Arginine 210.7 25.000 8.43 1.0 40 40,000 50 2OO 10 4 0 
3^ethylh lst id lne 彻.2 io 3.38 o.s 40 40,000 50 2OO 10 4 0 
Alanine 89.03 s.ooo 3.56 10 40 40,000 250 1000 50 2 0 0 
Taurine 125.1 10.000 5.00 1.0 40 40.000 m 4OO 20 8 0 
Tyrosine 飢2 26.ooo 7.25 1.0 40 40.000 50 2OO 10 4 0 
o(-Amino-n-butyric acid i<>3.i 1.000 4.12 1.0 40 40,000 50 2OO 10 4 0 
Va»ne 117.2 25.000 楊 i.o 40 40.000 m 4 O O 20 8 0 
Methionine 149.2 25,000 5.97 1.0 4o 40,000 50 2OO 10 4 0 
Tryptophan 204.2 1.000 a17 1.0 40 40,000 50 2OO 10 4 0 
Phenylalanine 俯.2 2s,ooo e.6i 1.0 40 40,000 50 2OO 10 4 0 
•soleucine 131.2 5.000 5.25 1.0 40 40.000 50 2OO 10 4 0 
Leucjne 131.2 2,000 5.25 1.0 40 40.000 ,oo 4OO 20 8 0 
Ornithine les.s 5,000 e 74 10 4n An nnn ir« i u 40 40,000 50 200 10 4 0 
Lysine 删 ioo.ooo 7.30 1.0 40 40,000 ,oo 4OO 20 80 
aIlo-isoIeucine i3i 25 5 .24 1 . 0 40 4o.ooo 5 0 2 O O fO 4 0 
ii-Alanine ss.i 100,000 356 10 an Annnn r« 
i u 如 叫咖 50 2 0 0 10 4 0 
Argininosuccinic acid 浏 so n.eo 1.0 40 40.000 50 2OO 10 4 0 
F.W. = Formula weight STD = standard 
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3.2.5 Internal standard 
Two internal standards, homoserine and norvaline were used. A solution 
consists of 600 ^molA. of each internal standard in O.lM HCL was prepared. 
The internal standard was aliquoted and stored in -30°C freezer 
3.3 SAMPLE PREPARATION 
In an eppendorf tube, 50 ^1 heparin plasma or composite standard solution was 
added to 30 ^1 internal standard solution. To precipitate out the protein, 420 ^1 
methanol added. The mixture was vortexed for 30 seconds and centrifuged at 
10000 g for 5 minutes. After centrifUgation, 100 jiil supematant was put into a 
HPLC vial.( vials obtained from Hewlett Packard). Then 30 i^l iodoacetic acid 
with concentration 80 mmoLL was added. The vials were vortexed and ready for 
injection. 
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3.4 CHROMATOGRAPHIC CONDITIONS 
3.4.1 Column Temperature 
Chromatographic separation was carried out at 30�C. The column chamber was 
maintain at the required temperature by heating blocks. 
3.4.2 Injector Program • 
The autosampler can hold 21 injection vials. The vial 1 was reserved to place the 
OPA derivatization reagent. An additional vial with Solvent A was placed in 
position 2. Such vial serves the purpose of rinsing the exterior side of the 
injection needle after aspirating the sample. 
In the injection program, OPA solution was drawn first, followed by sample. 
Then the needle was inserted into vial 2 in which solvent A was used to rinse the 
exterior side of the needle and finally dipped into vial 1 again so that another 
portion of OPA could be drawn. The OPA and the sample mixture were mixed 
in the sample loop by the movement of the needle piston. 
Just before injection into the analytical column, the mixture was held for certain 
period to give enough time for derivatization of the amino acid by OPA. 
Table 3-2 shows the autosampler program used. 
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Table 3.2 Autosampler program for OPA derivatization 
hiiector Program Remarks: 
1 Aspirate 2.0 口1 from air 
2 Draw 2.0 yd from vial 1 OPA solution 
3 Draw 10 yl from the sample placed at vial 3 - 21 
sample 
4 Draw 0.0 yil from vial 2 Solvent A in vial 2, to rinse the needle 
5 Draw 3.0 ^1 from vial 1 OPA solution again 
6 Mix, 5 times 
7 Wait for 2 minutes Time for derivatization 
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Table 3.3 Gradient profile of amino acid separation 
Time %ofSolventA %ofSolventB Flow Rate 
(rnVmin) 
0.00 100 0 1.50 
8.00 100 0 1.50 
11.00 90 10 1.50 
14.00 59 41 1.50 
16.50 54 46 0.50 
38.00 50 50 0.50 
39.00 50 50 1.00 
44.00 36 64 1.00 
44.50 35 65 0.40 
50.00 20 80 0.40 
51.00 0 100 0.40 
55.50 0 100 0.40 
56.00 0 100 0.15 
59.00 0 100 0.15 
59.50 0 100 0.10 
70.00 0 100 0.10 
71.00 100 0 1.00 
75.00 100 0 1.00 
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3.4.3 Time Table for gradient elution and flow program 
After optimization, the time necessary for individual run was 75 minutes. The 
amount of solvent A decreases gradually during the run from 100% to 0% while 
the solvent B increases gradually. To enhance good resolution and even 
distribution of the eluted amino acid peaks in the chromatogram, the flow rate in 
the run varied from 0.15 to 15 ml/min. Table 3-3 is the time table for gradient 
elution and flow program 
3.5 OPTIMIZATION 
3.5.1 OPA and sample Ratio and Volume 
The ratios 1:1, 1:2，1:3 and 1:4 was tried in order to find out a suitable 
composition of derivatization agent and methanol-treated sample. The total 
injection volume was at that stage arbitrary fixed to 12 i^l. For example, to get a 
1:1 ratio, 6 pil OPA was mixed with 6^1 treated sample while for ratio 1:2, 4yil 
OPA would be mixed with 8 ^1 treated sample, and so on. After obtaining a 
suitable ratio, different total injection volume was tried based on the ratio just 
obtained. 
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3.5.2 Derivatization Concentration 
A stock OPA solution was prepared by dissolving 50 mg powder in 1 ml 
methanol. Different concentrations of OPA was tried in order to find out the 
amount that was enough to derivatize all the amino acids present. Different 
amount of stock OPA was taken out to dissolve in the borate buffer solution, 
making concentration 1.92, 3.21 and 4.80 mg / ml. The 2-mercaptoethanol 
amount was adjusted accordingly giving concentration 1.5%, 2.6% and 3.8% 
respectively. 
3.5.3 Derivatization time 
After the aspiration and mixing of OPA and treated sample, the mixture was held 
and kept waiting in the injection loop for certain period of time for the 
derivatization reaction . Different waiting times, 2 minutes, 3 minutes and 4 
minutes, were tried out to find one with highest fluorescence signal. 
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3.6 ANALYTICAL PERFORMANCE 
3.6.1 Linearity testing 
A series of different concentration were formed using appropriate amount of 2 
levels of composite standards. The highest concentration of each individual 
amino acid was two times that of the high composite standard while the lowest 
concentration was one-fourth of the low composite standard. The coefficient of 
correlation, r, was calculated for each amino acid. 
3.6.2 Recovery studies 
High composite standard was spiked into a plasma sample. The concentrations 
of amino acid content were determined as well as the original amino acid 
concentrations in the plasma sample. The difference obtained was the individual 
amino acid recovered. Knowing the actual amino acid amount in the high 
composite standard, the percentage recovered can be calculated. 
3.6.3 Precision 
The within-run precision was obtained by analyzing a pooled plasma sample 
repeatedly within a run while the between-run precision was obtained by analyze 
the same sample in different run. A pooled plasma was analyzed 10 times in a 




A sample was stored in different conditions for short term to study the amino 
acid content changes in the period. A fresh sample was analyzed immediately 
while the remain was divided into six lots. Three of them were treated with 
methanol to remove protein and stored at 4°C, -20°C and -70°C respectively. The 
other three portions were stored as untreated plasma in the same temperature 
conditions as the treated. All the six aliquots were stored for two weeks and 
after that storage period amino acid content was analyzed. 
3.7 CLINICAL SAMPLE STUDIES 
The control group consists of 17 samples taken from 10 males and 7 females in 
Prince of Wales Hospital. Their age ranged from 23 to 46 with the median 33. 
Three groups of cancer patients were studied. They were colorectal cancer, lung 
cancer and nasopharyngeal cancer (NPC). The numbers of patient in each group 
were 10 ( 5 female and 5 female, with age ranged from 34 to 80 with median 69)， 
12 ( 8 male and 4 female, with age ranged 45 to 83 with median 72) and 12 (9 
male and 3 female, age ranged from 31 to 64 with median 52) respectively. All 
the cancer samples were randomly ordered in sequence to be analyzed. After 
analysis, they were then sorted according to their cancer type. 
About 10 ml blood was collected and put into 2 heparin bottles, each had amount 
about 5 ml. The plasma was separated for each bottle and aliquoted into 4-ml 
tubes. 
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3.8 STATISTICAL ANALYSIS 
Since the Student t test assumes normality in sample distribution, The data will 
be subjected to normality testing by plotting on the histogram before applying the 
Student t test. Since the number of cases in each group was small, the data may 
be failed in the normality testing. In case of failure�the non-parametric test 
would be used. The Mann-Whitney U Test (or Wilcoxon Test) is a non-
parametric counterpart of Student t test. It can test the difference between two 
independent means of each amino acid between the healthy control group and 
particular cancer group. 
In Mann-Whitney U Test, all the data are ranked no matter they come from 
control group or cancer group. The rank for each group summed. A U value is 
then calculated for each group, and s test of significance is applied to U. 
Besides testing for individual amino acid in healthy group and the cancer group, 
the amino acids were also grouped into branched-chain amino acid (BCAA), 
aromatic amino acid (AAA), essential amino acid (EAA) and non-essential amino 
acid QSfEAA). valine, leucine and isoleucine are branched-amino acid; while 
phenylalanine, tyrosine and tryptophan under aromatic amino acids. For essential 
amino acids, there are valine, leucine, isoleucine, phenylalanine, tryptophan, 
threonine and lysine, and lastly, glutamic acid, glutamine, glycine, alanine, serine, 
asparagine and tyrosine are all grouped as non-essential amino acids. Finally , 
the averaged total amino acid content in each group of cancer patients will be 
compared with that ofhealthy group. 
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4 RESULT 
4.1 CHROMATOGRAPHIC SEPARATION 
The 27 amino acids and 2 internal standards were resolved in 75 minutes. 
Distinct peaks were observed for all amino acids except there were partial 
overlapping peaks in citrulline and glycine. The first internal standard came out at 
about 20 minutes after injection and the second internal standard came out at 
about 50 minutes. 
Chromatograms of the high level standard and a normal plasma sample are 
shown in figure 4-1 and 4-2 respectively. 
The peaks came out in the first 35 minutes were governed by the first internal 
standard homoserine. The peak area ratio (PAR) was determined by dividing the 
peak area of particular amino acid by the peak area of homoserine. Similarly the 
peak area ratios of the amino acids came out after 35 minutes were worked out 
by reference to the peak area of the second internal standard, norvaline. 
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k. 
Figure 4.1 : Chromatographic separation ofHigh Composite Standard. 
Concentrations are Usted in Table 3.1. Column: Reverse-phase Cig Octadecyl 
Sulphate (ODS) column kept at 30�C. (250mm length X 4.6 mm I.D.,5 pm 
particle size, Hewlett Packard). Mobile-phase A: Acetonitrile, sodium propionate 
(0.25M)/phosphate buffer (0.35M), pH 6.5, water (8:15:77 v/v/v). Mobile phase 
B: Acetonitrile, methanol, dimethylsuIphoxide and water (30:25:3:42 v/v/v/v). 
Program for gradient elution Usted in Table 3.3. Detector HP1046A ^Hewlett 
Packard) used，with excitation wavelenth 230 nm and emission wavelength 418 
nm. 
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4.2.1 OPA and sample Ratio and Volume 
In the OPA and sample ratio studies, keeping the total injection volume 12.0 pl, 
the OPA amount decreases as the treated sample drawn increases. From Table 4-
1, we can see that the fluorescence increases as the amount of sample volume 
increased，up to the ratio 4pl: 8pl. Further increase in sample volume or 
decrease in ratio shows no further signal increment. So, a OPA to sample volume 
of 1:2 seems to be suitable. 
h the second part ofthe optimization, different total injection volume were tried 
while keeping the OPA to sample ratio 1:2. From Table 4-2，we can see that as 
the amount of OPA and sample volume increases, the fluorescence increased up 
to total injection volume 15 viL. No significant increase in fluorescence could be 
observed as the total injection volume was further increased to 18 pL. Bearing in 
mind that increase in total injection would cause decrease in peak resolution, so, 
the total injection volume was kept to 15 yiL for further studies. 
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Table 4.1 Optimization: OPA: Sample Ratio 
(Total injection Volume fixed to 12 uL) 
6+6 (vil) 4+8(pl) 3+9 (ul) 2+10(ul) 
Aspartic acid 21.35 18.36 9.56 4.95 
Glutamic acid 58.58 57.09 32.28 17.93 
Argininosuccinic acid 13.79 14.75 8.55 5.96 
Cystine 5.4 6 2.59 1.77 
Asparagine 28.94 31.13 22 16.58 
Serine 76.7 90.14 66.82 55.74 
Histidine 30.58 35.4 24.04 21.94 
Glutamine 426.44 493.06 372.98 306.56 
Homoserine (int std) 69.89 79.39 59.64 46.2 
Citrulline 76.39 89 64.47 51.38 
Glycine 362.02 474.36 490.25 538.22 
Threonine 110.69 116.05 79.73 60 
Arginine 70.08 84.02 69.17 68.62 
3-methylhistidine 37.56 41.85 27.92 23.02 
0-alanine 63.91 84.7 84.32 86.17 
Alanine 299.16 352.58 265.59 215.66 
Taurine 174.18 224.8 237.83 262.35 
Tyrosine 67.54 72.5 49.49 36.27 
a-Amino-n-butyric acid 19.04 21.68 15.33 11.29 
Methionine 41.62 47.7 36.97 29.94 
Norvaline (int std) 3578 39.74 27.97 20.02 
Tryptophan 38.95 43.96 32.93 25.28 
Phenylalanine 27.18 28.77 20.24 14.38 
Isoleucine 88.96 93.35 60.47 31.3 
alio-isoIeucine 70.56 66.69 42.38 24.39 
Leucine 136.84 149.63 108.27 50.53 
Ornithine 15.15 17.45 12.05 10.81 
Lysine 52.78 62.99 46.54 41.06 
2520.06 2937.14 2370.38 2078.32 
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Table 4.2 Optimization: Total Injection Volume 
(OPA:Sample Ratio fixed to 1:2) 
3+6^ d 4+8^ d 5+10 i^l 6+12nl 
Aspartic acid 13.87 18.36 18.74 16.53 
Glutamic acid 42.94 57.09 60.51 59.13 
Argininosuccinic acid 9.66 14.75 7.03 13.56 
Cystine 5.24 6 7.29 5.85 
Asparagine 22.14 31.13 38.14 40.42 
Serine 64.83 90.14 114.23 120.72 
Histidine 25.77 35.4 44.87 44.34 
Glutamine 345.04 493.06 588.93 593.52 
Homoserine (int std) 55.2 79.39 97.88 95.13 
Citrulline 61.69 89 110.38 104.62 
Glycine 333.16 474.36 624.32 629.98 
Threonine 81.17 116.05 140.87 134.53 
Arginine 58.42 84.02 113.29 109.07 
3-methyIhistidine 29.78 41.85 51.48 48.31 
fi-alanine 57.7 84.7 114.32 115.7 
Alanine 245.77 352.58 432.07 412.32 
Taurine 154.59 224.8 309.99 316.92 
Tyrosine 50.85 72.5 89.62 83.42 
a-Amino-n-butyric acid 15.38 21.68 26.93 27.63 
Methionine 32.35 47.7 55.47 57.55 
Norvaline (int std) 27.19 39.74 49.42 48.15 
Tryptophan 31.53 43.96 57.64 57.87 
Phenylalanine 19.6 28.77 35.76 34.84 
Isoleucine 42.28 93.35 103.3 81.43 
allo-isoleucine 46.24 66.69 83.51 55.03 
Leucine 106.51 149.63 192.45 182.32 
Ornithine 12.47 17.45 25.01 22.62 
Lysine 46.16 62.99 86.18 81.25 
2 0 3 7 . 5 3 2 9 3 7 . 1 4 3 6 7 9 . 6 3 3 5 9 2 . 7 6 
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4.2.2 Derivatization time 
It was the reaction time between the amino acids and the OPA derivatization 
agent. Different waiting time were tried. From Table 4-3, waiting time of 2 
minutes could give the highest total signals. Most of the amino acids reached 
their plateau fluorescence signal after 2 minutes. No significant increase in 
fluorescence signal can be observed if the reaction time was increased to 3 
minutes. The fluorescence signal started to decrease after 4 minutes, 
demonstrating the derivatization products were not so stable. The result also 
shows that standardization of derivatization time was important to obtain 
consistent results. 
4.2.3 OPA Concentration 
Three different OPA concentration were compared as shown in Table 4-4. The 
sample volume and the OPA volume were kept as 10 pL and 5 pL respectively. 
No further increase in fluorescence signal even the OPA concentration was 
increased from 1.92 to 3.21 and 4.80 mg/mL The limiting factor might be the 
amino acid amount present in the 10 pL sample. 
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Table 4.3 Optimization of Derivatization Time 
wait 1.0 wait 2.0 wait 3.0 wait 4.0 
Aspartic acid 14.14 21.5 24.6 i T o i 
Glutamic acid 49.01 64.92 75.47 67.6 
Argininosucdnic acid 16.04 18.98 19.61 19.96 
Cystine 3.1 6.41 9.58 9.03 
Asparagine 30.22 41.29 43.95 44.04 
Serine 100.53 126.49 129.23 126.68 
Histidine 41.29 48.27 48.21 44.6 
Glutamine 526.33 590.94 600.45 577.89 
Homoserine (int std) 87.84 100.2 101.66 97.04 
Citrulline 95.75 109.63 108.34 102.22 
Glycine 648.5 607.18 551.06 509.7 
Threonine 111.69 139.28 146.85 138.46 
Arginine 105.14 110.67 104.01 97.51 
3-methylhistidine 47.1 54.23 53.87 49.2 
fi-alanine 119.06 111.14 100.3 93.88 
Alanine 393.82 427.41 424.75 398.94 
Taurine 326.65 301.89 279.17 280.98 
Tyrosine 75.24 83.1 88.75 66.79 
a-Amino-n-butyric acid 22.66 28.77 29.21 28.52 
Methionine 55 63.91 63.16 60.2 
Norvaline (int std) 45.6 54.07 54.46 51.71 
Tryptophan 50.18 59.44 59.49 56.91 
Phenylalanine 28.98 36.69 38.13 37.21 
IsoIeucine 68.28 89.37 93.75 71.89 
allo-isoleucine 58.83 57.8 62.69 63.3 
Leucine 168.27 197.18 198.12 205.64 
Ornithine 25 26.01 23.77 21.63 
Lysine 85.27 90.95 84.7 77.3 
3399.52 3667.72 3617.34 3420.84 
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Table 4.4 Optimization of OPA Concentration 
1.92 3.21 4.80 (mg/ml) 
Aspartic acid 21.98 19.45 14.29 
Glutamic acid 68.31 63.91 49.85 
Argininosuccinic acid 17.5 15.97 12.34 
Cystine 8.71 7.26 5.41 
Asparagine 42.9 43.7 38.34 
Serine 137.28 134.88 118.11 
Histidine 48.86 48.76 42.43 
Glutamine 599.56 599.9 530.25 
Homoserine (int std) 99.33 100.38 87.83 
Citrulline 106.43 107.35 93.83 
Glycine 565.13 561.17 524.28 
Threonine 139.78 137.74 119.54 
Arginine 104.24 104.16 95.39 
3-methylhistidine 52.22 51.67 44.45 
0-alanine 100.77 101.73 93.92 
Alanine 406.02 406.94 345.52 
a-Amino-n-butyric acid 36.25 34.49 28.76 
Norvaline (int std) 54.84 55.5 46.78 
Tryptophan 61.74 60.23 55.29 
Phenylalanine 36.58 37.69 32.31 
Isoleucine 36.31 35.79 29.17 
allo-isoleucine 24.91 25.06 19.34 
Leucine 153.55 151.78 125.04 
Ornithine 24.79 23.54 21.34 
Lysine 86.45 83.26 73.59 
3034.44 3012.31 2647.4 
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4.3 ANALYTICAL PERFORMANCE 
4.3.1 Linearity 
The coefficients of correlation were calculated by plotting the peak area ratio , 
that was, the ratio of peak area of individual amino acid to that of the internal 
standard, against their concentrations. The linearity of the calibration curve could 
then be inspected. The r values for different amino acids were ranges from 0.992 
to 1.000. Such values indicates that the linearity's of the amino acids hold over 
wide ranges such as 10-400，20-800 and 50-2000 ^ o L L . The ranges can cover 
the amino acids amount in the most clinical samples. Figure 4-3 shows an 
example of the linear calibration curve formed. Linearity held over the range 50-
2000 ^moLl. for glutamine. Table 4-5 shows the coefficients of correlation of 
different amino acids. 
4.3.2 Recovery studies 
A plasma sample was spiked with high composite standard. Both the spiked and 
non-spiked plasma samples were analyzed. The percentage recovery was 
calculated from the following equation. 
Total amino acid measured - Amino acid in plasma sample measured 
% recovery = X 100% 
Amount of amino acid in composite standard 
Table 4-6 shows the percentage recovery of different amino acids. Their recovery 
ranges from 83% to 116 %. 
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Figure 4-3 Calibration and Regression Equation for Glutamine 
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Table 4-5 Linearity Testing : Coefficients ofcorrelation ofdifferent amino 
acids obtained. 
Range tested ( umol IL ) R-Square 
Aspartic acid 400 200 100 40 20 10 0.998 
Glutamic acid 800 400 200 80 40 20 0_999 
Argininosuccinic acid 400 200 100 40 20 10 0.999 
Asparagine 400 200 100 40 20 10 Q ggg 
Serine 800 400 200 80 40 20 Q 999 
Histidine 400 200 100 40 20 10 Q ggg 
Glutamine 2000 1000 500 200 100 50 1 QQQ 
Citrulline 400 200 100 40 20 10 1 QQQ 
Glycine 2000 1000 500 200 100 50 0 999 
Threonine 800 400 200 80 40 20 1 QQQ 
Arginine 400 200 100 40 20 10 Q ggy 
3-methylhistidine 400 200 100 40 20 10 Q ggg 
fl-alanine 400 200 100 40 20 10 Q 99g 
Alanine 2000 1000 500 200 100 50 1 QQQ 
Taurine 800 400 200 80 40 20 Q 993 
Tyrosine 400 200 100 40 20 10 1 QQQ 
a-Amino-n-butyric acid 400 200 100 40 20 10 1000 
Valine 800 400 200 80 40 20 1 QQQ 
Methionine 400 200 100 40 20 10 � g g g 
Tryptophan 400 200 100 40 20 10 1 QQQ 
Phenylalanine 400 200 100 40 20 10 1 QQQ 
lsoleucine 400 200 100 40 20 10 Q 993 
allo-isoleucine 400 200 100 40 20 10 Q gg^ 
Leucine 800 400 200 80 40 20 1 QQQ 
Ornithine 400 200 100 40 20 10 Q 的2 
Lysine 800 400 200 80 40 20 Q gg3 
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Table 4.6 Percentage recovery of different amino acids 
Amount spike (umol/L) % Recovery 
Aspartic acid 200 101 
Glutamic acid 400 92 
Argininosuccinic acid 200 95 
Cystine 400 116 
Asparagine 200 108 
Serine 400 110 
Histidine 200 96 
Glutamine 1000 103 
Citrulline 200 111 
Glycine 1000 100 
Threonine 400 105 
Arginine 200 113 
3-methylhistidine 200 102 
fi—alanine 200 101 
Alanine 1000 109 
Taurine 400 110 
Tyrosine 200 98 
a-Amino-n-butyric acid 200 110 
Valine 400 83 
Methionine 200 108 
Tryptophan 200 106 
Phenylalanine 200 103 
Isoleucine 200 86 
allo-isoleucine 200 102 
Leucine 400 97 
Ornithine 200 103 
Lysine 400 109 
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4.3.3 Precision Studies 
4.3.3.1 Within-run precision 
A pooled plasma sample was analyzed 10 times in a single run. The CV ranged 
from 2.4% to 8.8 % with an average 4.7%. 
Table 4.7 shows the within-run precision. 
4.3.3.2 Between-run precision 
y^(5ther plasma sample was analyzed 10 times in ten different run. The CV 
X ' • 
ranged from 2.3% to 10.9% with the exception of aspartic acid (13.7%) and 3-
methylhistidine (14.1%). The amino acid glutamine and alanine, with CV 2.9% 
and 2.3% respectively demonstrate the highest precision. 
Table 4.8 shows the between-run precision. 
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Table 4.7 Within-Run Precision (n=10) 
Plasma Concentration 
Mean S.D. C.V. 
(%) 
Aspartic acid 14.2 ± 1.1 7.7 
Glutamic acid 45.6 士 1.8 4.0 
Argininosuccinic acid nd 
Cystine nd 
Asparagine 42.6 土 1.0 2.4 Serine 79.0 士 2.4 3.0 Histidine 57.9 土 1 8 3.2 
Glutamine 411.2 ± 11.1 2.7 
Citrulline 26.3 土 2.2 8.5 
Glycine 164.3 士 12.8 7.8 
Threonine 9 8 . 6 土 3 . 7 3 . 8 
Arginine 50.5 士 2.3 4.6 
3-methylhistidine 1 9 . 6 ± 0 . 4 2.1 
15-alanine nd 
Alanine 220.9 士 5.9 2.7 
Taurine 55.6 土 3.9 7.1 
Tyrosine 68.2 土 2.1 3.0 
a-Amino-n-butyric acid 24.4 ± 0.6 2.3 
Valine 208.3 土 11.3 5.4 
Methionine 31.8 ± 1 4 4.5 
Tryptophan 40.4 土 1.5 3.6 
Phenylalanine 117.9 士 5.7 4.9 
Isoleucine 50.2 土 2.9 5.8 
allo-isoleucine nd 
Leucine 128.9 土 3.8 3.0 Ornithine 60.8 土 5.4 8.8 
Lysine 139.6 士 11.2 8.0 
(Average) 4.7 
S.D. = Standard deviation 
C.V = Coefficient ofVariation 
nd = not detected 
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Table 4.8 Between-Run Precision (n=10) 
Plasma Concentration 
1 ^ ^ s K c.v. (%) 
Aspartic acid 13.5 土 1.8 13.7 
Glutamic acid 56.4 ± 2 9 5.2 
Argininosuccinic acid 7.4 ± 0.8 10.8 
Cystine nd 
Asparagine 36.3 土 1.4 3.7 
Serine 77.8 士 3.4 4.4 Histidine 61.3 土 3.0 4.9 
Glutamine 483.2 ± 13 9 2.9 
Citrulline 33.2 ± 2.8 8.3 
Glycine 148.1 土 13.8 9.3 Threonine 89.5 ± 3.2 3.6 
Arginine 54.2 土 2.2 4.1 
3-methylhistidine 17.5 ± 2 5 14.1 
B-alanine nd 
Alanine 207.4 土 4.9 2.3 Taurine 46.7 土 4.9 10.5 
Tyrosine 50.6 土 1.8 3.6 
a-Amino-n-butyric acid 22.1 ± 2.3 10.6 
Valine 192.5 士 18.5 9.6 Methionine 24.7 土 2.7 10.9 
Tryptophan 31.8 土 2 1 6.7 
Phenylalanine 58.1 土 2 2 3.9 Isoleucine 46.1 ± 4.3 9.4 
allo-isoleucine nd 
Leucine 85.2 土 3.1 3.7 
Ornithine 57.0 ± 5 2 9.1 
Lysine 127.6 士 13.7 10.8 
(Average) 7.3 
S.D. = Standard deviation 
C.V = Coefficient of Variation 
nd = not detected 
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4.3.4 Sample storage studies 
Half of the amino acids showed significant change in concentrations when the 
samples were stored as original plasma at 4°C for two weeks. However, when 
such sample was pre-treated with methanol and stored as the same temperature, 
the dramatic changes were not observed. Significant increase in concentrations 
were shown by citrulline, phenylalanine and isoleucine no matter which 
temperature or condition they were being stored. Their increase were all larger 
than 20% of the original concentration.. No significant difference observed 
whether the sample were pre-treated or not when they were stored as -20°C and 
-70°C. These two temperature of storage gave similar outcome. Table 4-9 shows 
the ratio of amino acid amounts after storage to its original values obtained from 
the fresh sample. To sum up the findings, sample can be stored treated or 
untreated at -20°C or -70°C for short term, but never as original plasma 
untreated sample at 4°C. 
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Table 4-9 Sample Storage Studies. The ratio of amino acid amounts after 
storage to its original values obtained from the fresh sample shown. 
Plasma MeOH treated 
4 deg. -20 deg. -70 deg. 4 deg. -20 deg. -70 deg. 
Aspartic acid 1.75 1.10 1.18 1.08 1.15 1.18 
Glutamic acid 3.55 1.83 1.79 0.89 1.00 1.02 
Asparagine 0.58 0.98 1.03 0.92 0.96 1.01 
Serine 1.24 0.96 0.99 0.82 0.88 0.94 
Histidine 0.97 0.87 0.88 0.78 0.82 0.86 
Glutamine 0.25 0.75 0.76 0.75 0.83 0.88 
Citrulline 1.20 1.15 1.22 1.23 1.26 1.22 
Glycine 1.23 1.23 1.18 1.03 1.05 1.15 
Threonine 1.14 1.02 1.12 0.97 0.99 1.07 
Arginine 1.01 1.06 1.02 0.82 0.85 0.93 
3-methylhistidine 0.96 0.99 1.01 0.97 0.98 1 . 0 2 
B-alanine 0.97 1.00 0.98 0.96 0.97 0.99 
Alanine 1.15 1.01 1.00 0.90 0.93 1.00 
Taurine 0.88 0.99 0.93 0.88 0.89 0.95 
Tyrosine 0.96 1.00 1.02 0.93 0.97 1.03 
a-Amino-n-butyric acid 0.97 1.01 0.98 0.96 0.98 1.01 
Valine 0.98 1.13 1.06 1.04 1.01 1.08 
Methionine 1.11 1.27 1.06 1.10 1.02 1.06 
Tryptophan 1.03 1.02 1.00 0.93 0.96 1.01 
Phenylalanine 1.64 1.63 1.66 1.50 1.58 1.55 
Isoleucine 1.52 1.46 1.51 1.39 1.43 1.51 
allo-isoleucine 1.00 1.00 1.00 1.00 1.00 1.00 
Leucine 1.09 1.06 1.06 0.96 0.99 1.06 
Ornithine 1.32 1.07 1.03 0.84 0.89 0.99 
Lysine 1.04 1.15 1.06 0.86 0.91 0.99 
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4.4 CLEVICAL SAMPLE STUDY 
After grouping the cancer patients according to their sites of malignancy, 
plotting of the amino acid concentrations on the histogram revealed that most of 
the data were not normally distributed. Therefore the Student t test could not be 
used. Listead, the Mann Whitney U test, which is a non-parametric test with no 
assumption on data distribution was used. Figure 4-4 showed some of the 
histograms. 
In comparing the colorectal cancer group with the normal control group, four 
amino acid levels showed significant increase . They were aspartic acid, glutamic 
acid, 3-methylhistidine and taurine. Another four amino acids showed significant 
decrease. They were histidine, glycine, threonine and arginine. With the 
exception of glycine (p=0.029), other differences had significance value p<0.02. 
When the amino acids were grouped, both the total amino acid level, branch-
chain amino acid level, aromatic amino acid level and essential and non-essential 
amino acid levels did not have significant difference among the cancer group and 
the control group. 
The lung cancer group had eleven amino acid levels significantly different from 
that of the control group. Ten amino acids showed increase. They were aspartic 
acid, glutamine acid, glutamine, 3-methylhistidine, taurine, tyrosine, valine 
phenylalaine, isoleucine and ornithine. With the exception of taurine (p=0.0028), 
the other nine had p value < 0.02. The only one amino acid that showed 
significant decrease was histidine (<0.01). When the amino acids were grouped, 
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the branch-chained amino acids, aromatic amino acids, and the essential amino 
acids demonstrated differences when compared with the control group. Their 
levels of amino acids were all significantly elevated. 
When comparing the amino acid levels of nasopharyngeal cancer group with the 
control group, eight amino acids showed significant differences. Six amino acids 
had higher amino acid levels than the control group. They were aspartic acid， 
glutamic acid, 3-methylhistidine, alanine, a-amino-n-butyric acid and ornithine. 
Two amino acids were significant lower in levels, they were serine and arginine. 
After grouping the amino acids, all the total amino acid levels, branch-chained 
amino acid levels, aromatic amino acid levels and essential and non-essential 
amino acid levels were only slightly higher in the cancer group and showed no 
significant difference. 
Figure 4-5 to 4-7 showed chromatogram examples of each kind of cancer 
samples. Table 4-10, 4-11 and 4-12 show the amino acid concentration in 
colorectal, lung and nasopharyngeal cancer patients, and their comparisons with 
the normal control group. 
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Figure 4-4 Histograms of some amino acids in cancer samples. The amino acid 
concentrations on the histogram revealed that their distribution were not normal. 
The Student t test could not be used. ( The y-axis is the frequency in the cancer 
group; while x-axis is the concentration of the particular amino acid in ^mol/L) 
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Table 4-10: Plasma Amino Acid Concentrations in Colorectal cancer patient, as 
compared with the normal controls. The p values were obtained from the Marni 
Whitney U Test when compared the 2 sets of data. When the p value was less 
than 0.05, a comment was added to the right of the value to illustrated an 
increased or decreased level in the cancer amino acid level. 
Normal Controls Colorectal Cancer 
(n=17) (n=10) 
Mean S.D. Mean S.D. p 
Aspartic acid 9.3 2.5 13.9 1.9 0.000 increased 
Glutamic acid 54.9 51.4 75.3 23.1 0.008 increased 
Aparagine 39.9 4.6 36.5 8.4 0.103 
Serine 99.0 16.3 87.5 21.3 0.353 
Histidine 74.7 6.6 57.5 14.0 0.001 decreased 
Glutamine 514.1 89.7 445.1 78.2 0.067 
Citrulline 33.8 7.4 32.4 7.7 0.633 
Glycine 152.2 20.4 130.7 23.0 0.029 decreased 
Threonine 118.5 14.8 93.3 26.8 0.010 decreased 
Arginine 64.2 11.6 44.6 13.1 0.001 decreased 
3-methyUiistidine 15.9 1.2 18.2 1.4 0.001 increased 
Alanine 290.5 87.4 270.1 69.0 0.744 
Taurine 40.3 4.9 46.8 7.2 0.015 increased 
Tyrosine 57.9 12.3 56.8 16.0 0.782 
cx-Amino-n-butyric acid 23.4 3.6 25.1 5.3 0.498 
Valine 238.7 52.0 212.0 63.3 0.670 
Methionine 28.1 4.4 26.7 2.9 0.616 
Tryptophan 54.0 8.7 45.6 14.9 0.238 
Phenylalanine 49.3 5.4 57.3 16.2 0.093 
Isoleucine 65.5 18.8 63.2 20.9 0.980 
Leucine 111.1 23.1 93.1 29.4 0.167 
Ornithine 33.1 5.0 44.7 18.6 0.126 
Lysine 170.1 49.7 151.5 28.8 0.564 
TOTAL 2338.6 2 5 2 ^ ~ ~ 2 1 2 8 . 1 4 ^ 0 ^ 
BCAA 415.3 92.2 368.4 106.2 0.467 
AAA 161.2 21.9 159.7 39.0 0.436 
EAA 807.3 126.4 716.0 160.2 0.259 
NEAA 1208.6 150.2 1102.1 208.2 0.238 
EAA/NEAA 0.7 0.1 0.6 0.1 0.598 
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Table 4-11: Plasma Amino Acid Concentrations in Lung cancer patient, as 
compared with the normal controls. The p values were obtained from the Mann 
Whitney U Test when compared the 2 sets of data. When the p value was less 
than 0.05, a comment was added to the right of the value to illustrated an 
increased or decreased level in the cancer amino acid level. 
Normal controls Lung Cancer 
(n=17) (n=12) 
Mean S.D. Mean S.D. p 
Aspartic acid 9.3 2.5 14.7 2.2 0.000 increased 
Glutamic acid 54.9 51.4 92.8 37.3 0.000 increased 
Aparagine 39.9 4.6 41.2 10.7 0.808 
Serine 99.0 16.3 87.6 16.8 0.116 
Histidine 74.7 6.6 59.2 11.7 0.001 decreased 
Glutamine 514.1 89.7 479.8 90.4 0.259 
Citrulline 33.8 7.4 45.5 13.2 0.014 increased 
Glycine 152.2 20.4 147.5 32.2 0.674 
Threonine 118.5 14.8 112.3 32.0 0.207 
Arginine 64.2 11.6 60.6 17.8 0.259 
3-methylhistidine 15.9 1.2 20.1 2.0 0.000 increased 
Alanine 290.5 87.4 295.6 75.1 0.707 
Taurine 40.3 4.9 44.4 5.0 0.028 increased 
Tyrosine 57.9 12.3 82.6 22.7 0.002 increased 
a-Amino-n-butyric acid 23.4 3.6 21.8 5.7 0.184 
Valine 238.7 52.0 322.2 84.2 0.002 increased 
Methionine 28.1 4.4 31.6 14.1 0.674 
Tryptophan 54.0 8.7 55.3 16.5 0.740 
Phenylalanine 49.3 5.4 63.7 15.3 0.002 increased 
Isoleucine 65.5 18.8 85.1 23.9 0.018 increased 
Leucine 111.1 23.1 118.4 23.9 0.278 
Ornithine 33.1 5.0 64.9 21.7 0.000 increased 
Lysine 170.1 49.7 238.3 117.6 0.054 
TOTAL 2338.6 252.9 ~ ~ 2 5 8 4 . 8 4 ^ o J u 
BCAA 415.3 92.2 525.6 111.6 0.011 increased 
AAA 161.2 21.9 201.6 47.4 0.023 increased 
EAA 807.3 126.4 995.2 260.1 0.032 increased 
NEAA 1208.6 150.2 1227.1 190.7 0.912 
EAA/NEAA 0.7 0.1 0.8 0.2 0.012 increased 
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Table 4-12 : Plasma Amino Acid Concentrations in Nasopharyngeal cancer 
patient, as compared with the normal controls. The p values were obtained from 
the Mann Whitney U Test when compared the 2 sets of data. When the p value 
was less than 0.05, a comment was added to the right of the value to illustrated 
an increased or decreased level in the cancer amino acid level. 
Normal controls NPC Cancer 
(n=17) “ ( n = 1 2 ) “ 
Mean S.D. Mean S.D. p 
Aspartic acid 9.3 2.5 13.6 1.0 0.002 increased 
Glutamic acid 54.9 51.4 86.1 28.1 0.004 increased 
Aparagine 39.9 4.6 38.0 4.9 0.319 
Serine 99.0 16.3 87.3 10.2 0.040 decreased 
Histidine 74.7 6.6 69.1 9.1 0.106 
Glutamine 514.1 89.7 491.4 71.5 0.521 
Citrulline 33.8 7.4 36.8 4.8 0.298 
Glycine 152.2 20.4 147.1 14.1 0.521 
Threonine 118.5 14.8 108.4 19.9 0.177 
Arginine 64.2 11.6 54.4 7.0 0.018 decreased 
3-methylhistidine 15.9 1.2 20.3 1.7 0.000 increased 
Alanine 290.5 87.4 362.5 62.1 0.016 increased 
Taurine 40.3 4.9 42.9 5.0 0.097 
Tyrosine 57.9 12.3 60.5 5.3 0.207 
a-Amino-n-butyric acid 23.4 3.6 26.4 3.8 0.044 increased 
Valine 238.7 52.0 275.6 64.1 0.138 
Methionine 28.1 4.4 28.8 3.5 0.066 
Tryptophan 54.0 8.7 56.9 13.5 0.982 
Phenylalanine 49.3 5.4 53.5 12.6 0.740 
lsoleucine 65.5 18.8 75.2 19.1 0.177 
Leucine 111.1 23.1 103.3 20.2 0.364 
Ornithine 33.1 5.0 61.8 44.0 0.000 increased 
Lysine 170.1 49.7 194.8 78.5 0.808 
TOTAL 2338.6 252.9 ~ ~ 2 4 9 4 . 5 3 ^ 5 0 H 9 
BCAA 415.3 92.2 454.0 93.0 0.319 
AAA 161.2 21.9 171.0 23.1 0.241 
EAA 807.3 126.4 867.6 160.3 0.388 
NEAA 1208.6 150.2 1272.7 144.4 0.319 




For more than thirty years, the ion-exchange HPLC with post-derivatization using 
ninhydrin reagent was the basic configuration of the amino acid analyzer. The 
technology used was well-established. The set up could be ftilly automated with 
persistent good performance. However, the amino acid analyzer is a dedicated 
instrument and does not give feasibility for other assay using the same 
instrument. Besides, large amount of derivatization reagent was consumed during 
the run. 
With the advent of reversed-phase HPLC, it offered a good alternative for amino 
acid analysis. Versatility of the instrument allowed different derivatization agent 
to be used and as a result both sensitivity and selectivity enhanced. Automation is 
possible with the autosampler and autoinjector, but needs to be optimized. One 
main aim of this project is to optimize an automated protocol to be suitable for 
routine use. 
With the introduction of OPA as the derivatization agent, the sensitivity of the 
assay was tremendously increased. The detection limit could be down to 
fetomolar. Besides using as post-column derivatization agent, OPA could also be 
used in pre-colunm steps. It further offered an advantage that the trace amount of 
undesirable amino acids in the mobile phase would be derivatized and therefore 
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would not cause fluctuation in the baseline of the chromatogram. Noise 
elimination allowed detector operation at higher amplification. And therefore, 
very high sensitivity was ensured. No interference peak was produced since 
OPA itself did not have fluorescence. Besides strong fluorescence signal 
produced, OPA also gave fast reaction with the amino acids. The reaction 
carried out at room temperature as well. 
Compared with FMOC and Dansyl chloride method of derivatization, OPA 
offered higher sensitivity and clearer background; no tedious steps were 
involved in sample preparation. However, one of the drawback of using OPA as 
derivatization agent is that it cannot react directly with secondary amino acids 
proline and hydroxyproline. Secondary amino acids must be oxidized by 
hypochlorite or chloramine-T to render them detectable (Perrett, 1985). 
Besides the OPA products formed are not very stable and the quantity formed 
depends critically on the length of derivatization. Shortened derivatization time 
results in incomplete reaction while prolonged reaction time cannot guarantee the 
stability of the formed products. Therefore optimization of reaction time as well 
as sample volume, reagent volume, and reagent concentration was crucial to the 
success of the establishment of the reversed-phase HPLC method. 
To ensure reproducibility, the reaction time must be carefiilly controlled. 
Automatic sampler and injectors are critically important to the success of OPA 
pre-derivatization. The instrument must have the capability to aspirate sample 
and reagent for derivatization in different amount and at different order. The 
Hewlett Packard HP1050 system interfaced with the personal computer using the 
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Chem-Station software (Hewlett Packard) provide such feasibility. Under the 
program set, the sample and reagent, after mixing in the sample loop, were hold 
for designated period of time before injection into the column. The 
reproducibility of the outcome was therefore ensured. 
Without such automatic devices, the OPA derivatization steps would be difficult 
to carry out. The operator must do a mixing first, and hold the mixture for exactly 
certain interval, and inject into the column manually. Such manual steps has to be 
repeated after each sample run. Without the automatic derivatization device, as 
in some old HPLC model, FMOC is a good alternative to OPA for derivatization. 
It can detect secondary amino acids as well. The products formed are stable so 
batch derivatization becomes possible as time of reaction is not critical. 
However, solvent removal of excess FMOC reagent is necessary and its 
detection sensitivity is not as high as OPA. A preliminary attempt to establish a 
protocol utilizing FMOC as the derivatization agent has been made. But it was 
found to be labor intensive, mainly due to the need to remove excess FMOC and 
to condition the column. The attempt was not continued due to the constraint in 
time for completion of the whole project. However the OPA method established 
is proved to be satisfactory. All the 27 amino acids and 2 the internal standards 
were resolved, with no interference peak produced. The fluorescence signal 
produced was strong enough for quantitation. The derivatization procedure was 
fully automated. The setup could run on ovemight and more than 15 samples 
could be handled. Performance evaluation on precision, recovery, and linearity 
gave promised results. 
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In optimization procedures, an OPA:sample volume ratio was first worked out 
followed by finding a suitable injection volume for the mixture. Under a arbitrary 
total injection volume 12 pl, the OPA:sample ratio was varied in order to find the 
best combination in volume ratio that gave the strongest fluorescence signal. The 
ratio 1:2 was optimal. Theoretically, increase in injection amount of the 
determined 1:2 mixture would increase the fluorescence signal. However, 
increase injection volume would increase the burden of the column as well as 
ruin the resolution of the chromatographic peaks. The data obtained in injection 
volume optimization revealed that a total injection volume of 15 ^1 gave the 
strongest fluorescence signal. There was a about 20% decrease in signal if one 
employed the total volume of 12 pl. If the volume was increased to 18 yd, no 
further increase in signal obtained. Although the amount of derivatives formed 
increased, the deterioration of the derivatives was significant. Teerlink et al 
(1994) noticed that excess OPA accelerated degradation of its derivatives. So, 
optimization so as to adopt the minimal amount of OPA used is important. 
Different derivatization periods were tried. A reaction time of 2 minutes was the 
best and gave the highest fluorescence signals. It was the time that most the 
amino acids completed their derivatization with minimal fluorescence signal 
deterioration. Turaell and Cooper (1982) had carried out a study on amino acid 
OPA derivatives and noted that such amino acids such as glycine, taurine and 
ornithine had half-life less than 3 minutes. Worthen & Liu (1992) pointed out 
that when the waiting time was increased beyond 2.5 minutes, the stability of 
various amino acid was different. 
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Three different OPA concentrations were tried in the study. The concentrations 
being studied were those commonly employed by the previous workers. The 
alkaline OPA reagent ifheavily being injected into the column would damage the 
stationary phase inside. The lowest concentration of 1.92 mg/ml, which was 
originally being used in the earlier part of optimization studies, gave the strongest 
fluorescence signal. No significant increase in signal intensity was observed if the 
concentration was fiuther increased. Increase OPA concentration used by 
keeping the same total injection volume was an analogy of increasing the 
OPA:sample ratio, bicrease OPA amount alone would upset the previous optimal 
volume ratio. The results demonstrated that it was impossible to fiuther increase 
the OPA amount to gain higher fluorescence signal if the injection volume was 
kept constantly low so as to enhance resolution. 
The system takes 75 minutes to complete a single run. It can detect 27 amino 
acids. Most of the peaks in the chromatogram were satisfactorily resolved, with 
the exception ofpartial co-elution of citrulline and glycine. There was slight peak 
overlapping in taurine and tyrosine as well. Since the overall peak overlapping is 
not so serious, peak area was used to do the quantitative work. However, after 
several hundreds of injection, if the resolution of the peaks decrease, it is more 
wise to use the peak height for quantitation. McCoy et al (1984) noticed that for 
well-resolved chromatographic peaks, the precision of area measurement was 
equal or better than that ofheights measurement. However, in cases where peaks 
were poorly resolved, baseline showed perturbation, or where a peak eluted on 
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the tail of an earlier eluting peak, peak height measurements appeared to provide 
more precise quantitation. 
Deproteinization is necessary for amino acid analysis. As much as possible 
protein should be removed without affecting the amino acid concentration. 
Injection of protein into the column would shorten the column life. Methanol 
treatment was used in the work to remove protein in the plasma sample. It is an 
economical method with only simple precipitation and centrifugation steps. Most 
of the protein could be removed. 
For precision study, a pooled plasma was analyzed 10 times in a single nm to 
obtain the within-run precision. Another plasma sample was analyzed in 10 
separate run to obtain the between-run precision. The averaged coefficient of 
variation were 4.7% and 7.4% respectively. These figures are comparable with 
other methods such as ion-exchange HPLC (Moller,1993). So automatic sampler 
with programmed injector could ensure high precision since the reaction time as 
well as reaction volumes were properly controlled. 
In linearity study, all the amino acids demonstrated linearity from one-forth of the 
low composite standard concentration up to twice the amount of high composite 
standard. This ranges well cover all the physiological feasible ranges in human 
body. The coefficient of correlation r among different concentrations for each 
amino acid ranges from 0.992 to 1.000. Most of the amino acids got r values 
0.998 or above. 
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Recovery study is a measure of accuracy of the assay. Exact amount of analyses 
were spiked into one plasma sample. Recovery is a ratio index that reflects the 
amount that was measured out in the assay to its actual amount being spiked. 
The recovery values for different amino acids ranged from 92% to 110% with 
exception of cystine, citrulline, arginine, valine and isoleucine. 
In sample storage study, significant change in concentrations was observed if the 
untreated sample was stored at 4°C. Significant increases in aspartic acid (175% 
of original level) and glutamic acid (355%) were observed while asparagine 
(58%) and glutamine (25%) decreased drastically. Blundell and Brydon (1987) 
stated that it was essential to store samples at -70°C in order to prevent the 
formation of glutamic acid from glutamine and aspartic acid from asparagine. h\ 
the study glutamic acid still increased if the sample was stored untreated at -
20oC or -70oC. However, no change observed if the sample was treated before 
storage. No significant change in most amino acid concentration was observed 
if the samples were stored at -20°C or -70°C, if it had been treated with 
methanol . So, for short term storage, such as a period of about 2 weeks, the 
sample should be best stored at -20°C or -70�C with methanol treated. In case 
treatment cannot be done immediately, the plasma sample should be stored at -20 
°C but never at 4 °C. 
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5.2 CLINICAL 
5.2.1 Normal controls 
The free amino acid concentrations in the normal control agree with the reference 
ranges set by other local institute. Armstrong & Stave (1973) stated that there 
were significant differences between male and female in plasma amino acid 
concentrations. Men had amino acid levels higher than that of women in most of 
the amino acids, probably due to heavier muscular mass. However, in this study, 
the number of subject, both the control group and individual cancer group, was 
small and did not sub-divide into sex groups for comparison. 
Nutritional status ofboth the control group and the cancer groups were important 
factor. All the subjects should not have any weight loss or mal-nourishment. 
5.2.2 Colorectal Cancer 
In the colorectal cancer patient group, concentrations of eight amino acid were 
significantly different from the control group. Aspartic acid. Glutamic acid, 3-
methyl-histidine and taurine showed elevation in concentration while other 
histidine, glycine, threonine and arginine levels decreased. One non-essential 
amino acid, glutamic acid, elevated while another non-essential amino acid, 
glycine decreased in level. Threonine was the only one essential amino acid 
showed decrease in level. After grouping the amino acids, no significant different 
71 
in concentration observed in total, branch-chain, aromatic, essential and non-
essential amino acid levels. The only relationship among the altered amino acid 
levels were histidine and 3-methyl-histidine. 3-methyl-histidine is formed from 
histidine methylation on actin and myosin. Its level reflects the skeletal muscle 
breakdown since it is not re-utilize for protein synthesis nor metabolize to other 
product. 
Similar results had been obtained by other workers. Ching et al (1984) and 
Psister et al (1992) both studied gastro-intestinal malignancy found that there 
were no difference in plasma amino acid levels between the cancer group and the 
normal control group. Increase in amount of aspartic acid, glutamic acid and 
taurine in colorectal cancer patients agreed with the findings of Zhang and Pang 
(1992). 
Since the increased and the decreased of amino acids belonged to different 
groupings, there was no specific change to the amino acid grouping. Generally, 
colorectal cancer patient may have some problem in absorption of essential 
amino acids from the daily food. Since the patient were newly-diagnosed, such 
change in amino acid levels at that stage might not pronounced. 
5.2.3 Lung Cancer 
About half of the amino acids had levels significantly different from those ofthe 
control group. The only one amino acid that showed decrease in level was 
histidine. Ten amino acids showed elevation in amino acid levels. They were 
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aspartic acid, glutamic acid, citrulline, 3-methyl-histidine, taurine, tyrosine, 
valine, phenylalanine, isoleucine and ornithine. Out of 10 amino acids there were 
4 essential and 2 non-essential. And in this 6 essential and non-essential amino 
acids, there were 2 aromatic and 2 branch-chain amino acids. As a consequence, 
after grouping of the altered level amino acids, The essential, branch-chain and 
the aromatic amino acids were significant different from the control group. 
The increases in aspartic acid，glutamic acid, taurine and ornithine agreed with 
that of Zhang & Pang (1992), as well as decrease in histidine. However, the 
increase in essential amino acid levels, both the branch-chain and aromatic, 
contradicted with Nanini et al (1988) and Zhang & Pang (1992) . The 
unexpected elevation of essential amino acid levels might be due to the diet of 
the patients. The essential to non-essential ratio was increased in this group of 
cancer patient. Such increase had no clinical significant. Only a low essential to 
non-essential ratio has clinical significance indicating under nourishment. 
5.2.4 Nasopharyngeal Cancer 
In nasopharyngeal cancer group of patients, there were eight amino acids that the 
levels were significantly different from the control group. Six amino acids 
showed increase in level. They were aspartic acid, glutamic acid, 3-methyl-
histidine, alanine, a-amino-n-butyric acid, and ornithine. The two amino acids 
that showed decrease in level were serine and arginine. Serine and alanine were 
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non-essential amino acids , that the former showed decreased in level while the 
latter showed increase in level. The other six amino acids did not belong to any 
particular group. After grouping, the total, branch-chain, aromatic, essential, and 
non-essential amino acids were not significantly different from the control group. 
Since the nasopharyngeal cancer are not very common in westem population, 
similar data cannot be found for comparison. 
5.2.5 Summary 
Consistent with Zhang & Pang findings, all the cancer group demonstrated 
elevation in aspartic acid and glutamic acid. Moreover，the 3-methyl-histidine 
level was increased in all the three group of cancer patients. Such amino acid was 
come from histidine. Histidine level was decreased in colorectal and lung cancer 
patients. For nasopharyngeal cancer patients, histidine level, although decreased, 
but not significant as the other two groups. After grouping ofthe amino acids, the 
colorectal and nasopharyngeal cancer patients did not demonstrated any 
difference in any particular group of amino acid. For lung cancer, the essential 
amino acid increased significantly, which included some aromatic and branch-
chain amino acid. Dietary factor might contribute to such difference. So, in 
summary, the newly-diagnosed cancer patient with minimal weight loss had 
amino acid pattem similar to the well-nourished control group. 
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6. CONCLUSION 
The reverse-phase HPLC using OPA in pre-column derivatization was set up and 
had been optimized. The analytical performance was found to be satisfactory. 
Cancer sample studies revealed that the concentrations of some amino acid were 
altered in newly-diagnosed cancer patients. However，the change at that stage 
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